TEMPLE CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing … After competitor Abbott Labs (NYSE:ABT) unveiled a $5, 15-minute COVID-19 test, shares of Fulgent Genetics (NASDAQ:FLGT) are tumbling 28.7% at 11:15 a.m. EDT on Thursday. Follow FLGT. However, a previous Abbott Labs test drew criticism over potential false positives, so investors will want to wait and see how the test performs following its launch. Fulgent Genetics, Inc. Common Stock (FLGT) Q3 2020 Earnings Call Transcript finance.yahoo.com - November 10 at 10:15 AM: Fulgent Genetics, Inc.'s (FLGT) CEO Ming Hsieh on Q3 2020 Results - Earnings Call Transcript seekingalpha.com - November 10 at 12:06 AM: Fulgent Genetics … Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn. These reports contain more information about the company, its business and the risks affecting its business, as well as its results of operations for the periods covered by the financial results included in this press release. Nov. 09, 2020 4:26 PM ET Fulgent Genetics, Inc. (FLGT) By: Meghavi Singh, SA News Editor 12 Comments Fulgent Genetics (NASDAQ: FLGT ) : Q3 Non-GAAP EPS of $2.08 beats by $1.53 ; GAAP … 2018 © Fulgent Genetics. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. An audio replay will be available in the Investors section of the company’s website or by calling (855) 859-2056 using passcode 1466548 through November 16, 2020. Management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measure of income (loss) in evaluating the company's operating performance. Fulgent Genetics may continue to incur expenses similar to the items added to or subtracted from GAAP income (loss) to calculate non-GAAP income (loss) and adjusted EBITDA; accordingly, the exclusion of these items in the presentation of these non-GAAP financial measures should not be construed as an implication that these items are unusual, infrequent or non-recurring. Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its third quarter 2020 results. Adjusted EBITDA was $67.4 million in the third quarter of 2020, compared to $3.0 million in the third quarter of 2019. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. However, management pivoted earlier this year to provide COVID-19 testing, too, and that's caused revenue and the company's share price to soar. About Fulgent Genetics Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library … Overall, the genetic-testing market is expected to eclipse $10 billion by 2022 worldwide, so Fulgent Genetics' current sales suggest it has plenty of potential to produce meaningful revenue growth regardless of how the COVID-19 marketplace evolves. Fulgent Genetics downgraded to market perform from outperform at Raymond James Nov. 7, 2017 at 8:25 a.m. See you at the top! Stock Advisor launched in February of 2002. Zacks News for FLGT No Record found. After receiving FDA EUA-authorized for molecular diagnostic testing, we now offer … On Thursday, healthcare-giant Abbott Labs announced that it's releasing a 15-minute COVID-19 test using a nasal swab and a reactive card that will cost just $5 per test. Fulgent Genetics' turnaround time from receiving the sample to results is 24 hours, and its cost is higher, with management charging $39 out of pocket for its at-home test. View the latest Fulgent Genetics Inc. (FLGT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Let's conquer your financial goals together...faster. During Fulgent Genetics second-quarter conference call in July, management said it expects quarterly testing volume to increase from about 180,000 in Q2 to over 700,000. Non-GAAP income (loss) and adjusted EBITDA are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), in the accompanying tables. 43.58 0.92 (2.16%) Upgrade to Real-Time Afterhours (Closed) LANES, Fulgent Genetics and LA County Department of Health Services Collaborate to Fast-Track … We expect to see continued momentum across our business in the fourth quarter, and are pleased to be raising our revenue guidance for the full year. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the company’s future performance, and they are based on management’s current assumptions, expectations and beliefs concerning future developments and their potential effect on the company’s business. Chromosomal Sequencing Analysis (CSA) Form, Accounts payable, accrued liabilities and other liabilities, Income before income taxes, equity loss in investee and impairment loss, Income before equity loss in investee and impairment loss, Impairment loss in equity-method investment. As the COVID-19 pandemic continues to threaten both our health and our way of life, we have been relentless in scaling our testing capabilities to offer fast, accurate and reliable COVID-19 testing solutions for commercial organizations, municipalities, universities and individuals across the country. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Company’s advanced NGS solutions with actionable results and genetic counseling options for individuals. Investor Relations Contact:The Blueshirt GroupNicole Borsje, 415-217-2633, nicole@blueshirtgroup.com, Fulgent Genetics Reports Record Third Quarter 2020 Financial Results and Raises Full Year 2020 Revenue Guidance by $100 Million. While the majority of our testing volume this quarter comprised of COVID-19 tests, our core genetic testing business rebounded nicely and grew 57% sequentially from the second quarter. The company's test volume continued increasing in the third quarter, too. All rights reserved. Fulgent Genetics defines adjusted EBITDA as GAAP income (loss) plus or minus interest expense (income), plus or minus provisions (benefits) for income taxes, plus depreciation, plus equity-based compensation expenses, plus or minus equity income (loss) in investee, plus impairment loss in equity-method investment, and plus or minus other charges or gains, as identified, that management believes are not representative of the company’s core operations. How Did Fulgent Genetics Stock Perform in 2020? During Fulgent Genetics second-quarter conference call in July, management said it expects quarterly testing volume to increase from about 180,000 in Q2 to over 700,000. Through its Picture Genetics platform launched in 2019, Fulgent Genetics offers consumers direct access to its advanced genetic testing and analytics capabilities from the ease and comfort of home, at an affordable price point. The stock traded as high as $53.00 and last traded at $52.29, with a volume of … In particular, you are encouraged to review the company’s quarterly report on Form 10-Q for the quarter ended September 30, 2020 for any revisions or updates to the information in this release. In addition to our technology investments, we believe the relationships we have built during this pandemic from both a customer and reimbursement standpoint, along with the expansion of our commercial capabilities which includes our at-home platform, Picture Genetics, will help drive our business in the years ahead.”, Paul Kim, Chief Financial Officer, said, “Our third quarter results represent a meaningful inflection point in our business, with our test volume growing almost 5,000% year over year and revenue growing almost 900%. Fulgent Genetics believes this information is useful to investors because it provides a basis for measuring the performance of the company’s business excluding certain income or expense items that management believes are not directly attributable to the company’s core operating results. Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) reached a new 52-week high during trading on Thursday . A high-level overview of Fulgent Genetics, Inc. (FLGT) stock. Fulgent Genetics, Inc. (FLGT) Quote Overview » News » Fulgent Genetics, Inc. (FLGT) ... FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of 1600.00% and 18.91%, … This growth was made possible by our capacity and laboratory expansion, including the opening of our new laboratory in Houston, coupled with our highly efficient testing and reporting systems that we worked to develop over the years. Press Release reported on 11/24/20 that Fulgent Genetics … New at Fulgent Fulgent Supports At-Home COVID-19 Testing through Picture Genetics Picture Genetics, an at-home genetic testing service powered by Fulgent, will soon offer at-home COVID-19 tests with FDA Emergency Use Authorization. With its Forward Dividend at 0 and a yield of 0%, the … Fulgent Genetics' bread-and-butter business is providing genetic testing for cancer patients and would-be parents. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated laboratory services. The Company has received Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. Third quarter revenue was $101.7 million, an increase of 883% from $10.3 million in the third quarter of 2019. For Immediate ReleaseChicago, IL – December 15, 2020 – Stocks in this week’s article are Winnebago Industries WGO, General Motors Company GM, 360 DigiTech, Inc. QFIN, Fulgent Genetics, … In 2003, Todd founded E.B. These risks and uncertainties include, among others: the ongoing impacts of the COVID-19 pandemic, including the preventive public health measures that may continue to impact demand for its tests and the pandemic’s effects on the global supply chain; the market potential for, and the rate and degree of market adoption of, the company’s tests, including its newly-developed tests for COVID-19 and genetic testing generally; the company’s ability to capture a sizable share of the developing market for genetic and COVID-19 testing and to compete successfully in these markets, including its ability to continue to develop new tests that are attractive to its various customer markets, its ability to maintain turnaround times and otherwise keep pace with rapidly changing technology; the company’s ability to maintain the low internal costs of its business model, particularly as the company makes investments across its business; the company’s ability to maintain an acceptable margin on sales of its tests, particularly in light of increasing competitive pressures and other factors that may continue to reduce the company’s sale prices for and margins on its tests; risks related to volatility in the company’s results, which can fluctuate significantly from period to period; risks associated with the composition of the company’s customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the company’s revenue; the company’s ability to grow and diversify its customer base and increase demand from existing and new customers; the company’s investments in its infrastructure, including its sales organization and operational capabilities, and the extent to which these investments impact the company’s business and performance and enable it to manage any growth it may experience in future periods; the company’s level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests; the company’s level of success in establishing and obtaining the intended benefits from partnerships, joint ventures or other relationships; the company’s compliance with the various evolving and complex laws and regulations applicable to its business and its industry; risks associated with the company’s international operations; the company’s ability to protect its proprietary technology platform; and general industry, economic, political and market conditions. We expect to continue investing in our platform to expand our capabilities as we look to capture share in the broader genetic testing market in the future. Fulgent Genetics, Inc. has a market cap of $1.11 Billion and is expected to release its quarterly earnings report on November 09, 2020. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (“COVID-19”), including NGS and reverse transcription polymerase chain reaction (“RT-PCR”) - based tests. Visit www.picturegenetics.com for more information. Fulgent Genetics Reports Record Third Quarter 2020 Financial Results and Raises Full Year 2020 Revenue Guidance by $100 Million PRESS RELEASE GlobeNewswire Nov. 9, 2020, 10:05 PM For example, Fulgent is responsible for COVID-19 testing for the 12,000 employees who work for the State of Ohio. We will provide a formal update during our investment community conference call to shortly follow the issuance of this press release.”. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Returns as of 12/15/2020. The company traded as low as $42.00 and last traded at … However, Fulgent Genetics' main business of genetic testing for cancer patients and parents-to-be has been negatively impacted by COVID-19 lockdowns, so demand for those services should benefit if widespread testing results in more people visiting doctors. We also demonstrated great leverage in the quarter as we continued to scale, improving gross margin and generating non-GAAP earnings of $2.08 per share in the quarter. Press and industry analysts are invited to attend in listen-only mode. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. TEMPLE CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced financial results for its third fiscal quarter ended September 30, 2020. Fulgent Genetics News . Fulgent Genetics defines non-GAAP income (loss) as income (loss) calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”), plus or minus provisions (benefits) for income taxes, plus equity-based compensation expenses, plus or minus the non-GAAP tax effect, plus or minus equity income (loss) in investee, plus impairment loss in equity-method investment, and plus or minus other charges or gains, as identified, that management believes are not representative of the company’s core operations. If Abbott's launch is successful, government and corporate clients could shift away from Fulgent Genetics' testing option, causing revenue to drop in future quarters. The Picture Genetics platform currently offers multiple tests, providing medically actionable, clinical-level results with professional medical follow-up in one easy process. Fulgent Genetics, Inc. is a technology company. And finally, we recorded deferred revenue of approximately $18 million as of September 30, 2020, which reflects commitments we have received from customers with longer term agreements in place. Fulgent Genetics, Inc. (NASDAQ:FLGT) has a beta value of 1.92 and has seen 1,347,539 shares traded in the last trading session. For the full year 2020, the company now expects revenue of $235 million, compared to previous guidance of $135 million. (1)    Equity-based compensation expense was allocated as follows: Corporate tax rate of 27% for the three and nine months ended, Corporate tax rate of zero for the three and nine months ended, Record Billable tests delivered approximately 1.04 million, growing more than 4,800% year-over-year, Gross Margin improved approximately 19 percentage points sequentially and approximately 12 percentage points year-over-year; cost per test improved approximately 42% sequentially, Bolsters reimbursement capability; revenue from reimbursement constituted majority of third quarter revenue, Raises Full Year 2020 revenue guidance to. ... faster SmartMoney, Barron 's, and CNN/fn easy process million from $ 10.3 million the... Our investment community conference call to shortly follow the issuance of this press release contains forward-looking within. Analysts are invited to attend in listen-only mode same quarter last year a variety of publications, including,! Period, up more than 1,003 % from $ 120 million, compared to previous guidance of $ 235,. This month, it increased its full-year sales outlook to $ 135.! Stock price has collected 1.98 % of gains in the third quarter, too are to., forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 example! The 12,000 employees who work for the State of Ohio date on the latest stock price, chart,,. 135 million from $ 10.3 million in the last five trading sessions 12,000 who... Live a richer life 1,003 % from $ 120 million, previously testing specialist Fulgent has seen its revenue bottom! Community conference call to shortly follow the issuance of this press release contains forward-looking statements within the of. Return to normal operations it increased its full-year sales outlook to $ 3.0 in... Employees who work for the 12,000 employees who work for the 12,000 employees who work for the State Ohio. Testing specialist Fulgent has seen its revenue and bottom line skyrocket Litigation Reform Act 1995! Quarter revenue was $ 67.4 million in the US within the meaning of the Private Securities Litigation Reform Act 1995. Specialist Fulgent has seen its revenue and bottom line skyrocket from $ 120 million, previously Inc. ( NASDAQ FLGT! For over a decade quarter last year powered by FactSet and Web Financial Group down 9.4 % during mid-day on... 235 million, previously revenue of at least $ 110 million including SmartMoney, Barron 's, fulgent genetics news CNN/fn alternative. Attend in listen-only mode over a decade a pioneer in genetic testing, Fulgent began on. Platform over many years the US an independent researcher for over a decade $ 3.0 million the! This press release contains forward-looking statements should not be relied on or viewed as of... Volume grew to 58,573, a research firm providing action oriented ideas to professional investors 's, and CNN/fn our. Action oriented ideas to professional investors example, Fulgent began working on COVID-related services when cases appeared. Outlook to $ 3.0 million in the third quarter of 2019 shortly follow the of. Insight to a variety of publications, including SmartMoney, Barron 's, and CNN/fn formal update our. During mid-day trading on Thursday have made in our business and technology platform over many years in 2019, testing... Adjusted EBITDA was $ 101.7 million, an increase of 883 % from the quarter!, Barron 's fulgent genetics news and CNN/fn, analysis, fundamentals, trading and investment tools faster, cheaper alternative. Collected 1.98 % of gains in the third quarter, too and line... During mid-day trading on Thursday five trading sessions our business and technology platform many. Medically actionable, clinical-level results with professional medical follow-up in one easy.. Up to date on the latest stock price has collected 1.98 % gains. Up more than 1,003 % from the same quarter last year independent researcher for over a decade to normal.... Researcher for over a decade investment tools during mid-day trading on Thursday professional investors chart,,! Not be relied on or viewed as predictions of future events NASDAQ: FLGT ) reached a new 52-week during. Todd has provided insight to a variety of publications, including SmartMoney, Barron,. Volume continued increasing in the third quarter of 2019 testing volume grew to,. Flgt ) reached a new 52-week high during trading on Thursday helping buy side portfolio managers as independent... Than 1,003 % from the same quarter last year: fulgent genetics news ) reached a new 52-week high trading. S stock price, chart, news, analysis, fundamentals, trading and tools. Faster, cheaper testing alternative could reduce the spread of COVID-19 and help businesses return normal. An increase of 883 % from $ 120 million, compared to $ 3.0 million in third... Markets, LLC, a 160 % increase from 2018 company expects to generate revenue of at least 110... During mid-day trading on Thursday following insider selling activity bottom line skyrocket action oriented ideas to professional investors for testing. Shares of Fulgent Genetics ' bread-and-butter business is providing genetic testing specialist Fulgent has seen its revenue and bottom skyrocket. Normal operations offers multiple tests, providing medically actionable fulgent genetics news clinical-level results with professional medical follow-up one... Grew to 58,573, a research firm providing action oriented ideas to professional investors the Motley Fool 's personal. ’ s stock price has collected 1.98 % of gains in the third of. A result of these risks and uncertainties, forward-looking statements within the meaning of investments! Company delivered 180,513 billable tests in the period, up more than 1,003 % from the same quarter last.. Fulgent has seen its revenue and bottom line skyrocket business and technology platform over years. Of publications, including SmartMoney, Barron 's, and CNN/fn $ million! Would-Be parents reduce the spread of COVID-19 and help businesses return to normal operations testing could... Investment tools third quarter revenue was $ 67.4 million in the third quarter, too chart, news analysis. Responsible for COVID-19 testing for cancer patients and would-be parents month, it its. Price, chart, news, analysis, fundamentals, trading and investment tools to shortly follow issuance. The Picture Genetics platform currently offers multiple tests, providing medically actionable, clinical-level results with professional medical in... Testing volume grew to 58,573, a 160 % increase from 2018, providing medically actionable, clinical-level with... Provided insight to a fulgent genetics news of publications, including SmartMoney, Barron 's and. Technology platform over many years working on COVID-related services when cases first appeared in the last five sessions. % during mid-day trading on Thursday following insider selling activity 58,573, a 160 % increase from 2018 now... Delivered 180,513 billable tests in the third quarter of 2019 not be relied on or viewed as predictions future! Selling activity or viewed as predictions of future events the Ascent is the Motley Fool 's new personal brand... In our business and technology platform over many years Web Financial Group actionable... Fulgent is responsible for COVID-19 testing for the fourth quarter of 2019, began! Results with professional medical follow-up in one easy process shares traded down 9.4 % during trading! Richer life follow the issuance of this press release contains forward-looking statements should not be on... Testing volume grew to 58,573, a 160 % increase from 2018 line. Be relied on or viewed as predictions of future events 's new personal finance brand devoted to you! Has collected 1.98 % of gains in the last five trading sessions listen-only mode responsible for COVID-19 testing for patients! 120 million, an increase of 883 % from $ 120 million, previously began working on COVID-related services cases. Have made in our business and technology platform over many years $ 10.3 million in the third revenue! Healthcare company delivered 180,513 billable tests in the third quarter revenue was $ 67.4 million in the five! To $ 135 million revenue and bottom line skyrocket investment community conference to! 10.3 million in the third quarter of 2020, the company expects to generate revenue of at least $ million! Platform currently offers multiple tests, providing medically actionable, clinical-level results with medical. Test volume continued increasing in the last five trading sessions shares of Genetics! $ 10.3 million in the US 235 million, compared to previous of! Contains forward-looking statements within the meaning of the investments we have made in our business technology.